The Value of Liver and Spleen Stiffness for Evaluation of Portal Hypertension in Compensated Cirrhosis

Thomas Reiberger – 13 December 2021 – Patients with compensated advanced chronic liver disease who develop clinically significant portal hypertension (CSPH) are at high risk for hepatic decompensation and mortality if left untreated. Liver biopsy and hepatic venous pressure gradient (HVPG) measurements are the current gold standard procedures for determining fibrosis severity and diagnosing CSPH, respectively; however, both are invasive, limiting their use in clinical practice and larger trials of novel agents.

Aiming for Functional Cure With Established and Novel Therapies for Chronic Hepatitis B

Hannah S.J. Choi, Alexander Tonthat, Harry L.A. Janssen, Norah A. Terrault – 9 December 2021 – Chronic hepatitis B virus (HBV) infection remains difficult to cure due to the persistent, self‐replenishing nature of the viral genome and impaired host immune responses. Current treatment goals for chronic hepatitis B (CHB) are to prevent or significantly delay liver‐related adverse outcomes and death, and two types of treatments are available: nucleos(t)ide analogues (NAs) and interferons (IFNs).

NASHFit: A randomized controlled trial of an exercise training program to reduce clotting risk in patients with NASH

Jonathan G. Stine, Ian R. Schreibman, Alison J. Faust, Jessica Dahmus, Benjamin Stern, Christopher Soriano, Gloriany Rivas, Breianna Hummer, Scot R. Kimball, Nate R. Geyer, Vernon M. Chinchilli, Rohit Loomba, Kathryn Schmitz, Christopher Sciamanna – 9 December 2021

MutT Homolog 1 Inhibitor Karonudib Attenuates Autoimmune Hepatitis by Inhibiting DNA Repair in Activated T Cells

Yong Chen, Xiangwei Hua, Bingyuan Huang, Stella Karsten, Zhengrui You, Bo Li, You Li, Yikang Li, Jubo Liang, Jun Zhang, Yiran Wei, Ruiling Chen, Zhuwan Lyu, Xiao Xiao, Min Lian, Jue Wei, Jingyuan Fang, Qi Miao, Qixia Wang, Ulrika Warpman Berglung, Ruqi Tang, Thomas Helleday, Xiong Ma – 9 December 2021 – Autoimmune hepatitis (AIH) is an inflammatory liver disease driven by the hyperactivation of various intrahepatic antigen‐specific T cells due to a breach of immune tolerance.

Subscribe to